Evidence map›Paper›PMID 23902719›Full record

ArticleMultidisciplinary respiratory medicine2013

The value of FeNO measurement in childhood asthma: uncertainties and perspectives.

Giuliana Ferrante, Velia Malizia, Roberta Antona, Giovanni Corsello, Stefania La Grutta

Open access · goldAbstract read
In one paragraph

Article in Multidisciplinary respiratory medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. The Relationship of Fractional Exhaled Nitric Oxide in Patients with AECOPD.International journal of chronic obstructive pulmonary disease · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Immunological and toxicological risk assessment of e-cigarettes.European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Giuliana Ferrante *Institute of Biomedicine and Molecolar Immunology, National Research Council, Palermo, Italy.
Velia Malizia *Institute of Biomedicine and Molecolar Immunology, National Research Council, Palermo, Italy.
Roberta Antona *Institute of Biomedicine and Molecolar Immunology, National Research Council, Palermo, Italy.
Giovanni Corsello *Department for Health Promotion and Mother and Child, Università di Palermo, Italy.
Stefania La GruttaInstitute of Biomedicine and Molecolar Immunology, National Research Council, Palermo, Italy.
National Research Council · ITUniversity of Palermo · ITIstituto di Biomedicina e di Immunologia Molecolare Alberto Monroy · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asthma is considered an heterogeneous disease, requiring multiple biomarkers for diagnosis and management. Fractional exhaled nitric oxide in exhaled breath (FeNO) was the first useful non-invasive marker of airway inflammation in asthma and still is the most widely used. The non-invasive nature and the relatively easy use of FeNO technique make it an interesting tool to monitor airway inflammation and rationalize corticosteroid therapy in asthmatic patients, together with the traditional clinical tools (history, physical examination and lung function tests), even if some controversies have been published regarding the use of FeNO to support the management of asthma in children. The problem of multiple confounding factors and overlap between healthy and asthmatic populations preclude the routine application of FeNO reference values in clinical practice and suggest that it would be better to consider an individual "best", taking into account the context in which the measurement is obtained and the clinical history of the patient. Besides, there is still disagreement about the role of FeNO as a marker of asthma control, due to the complexity of balance among the different items involved in its determination and the lack of homogeneity in the population groups studied in the few studies conducted so far. Heterogeneity of problematic severe asthma greatly limits utility of FeNO alone as a biomarker of inflammation to optimize the disease management on an individual basis. None of the studies conducted so far demonstrated that the use of FeNO was better than current asthma guidelines in controlling asthma exacerbations. In summary, there is a large variation in FeNO levels between individuals, which may reflect the natural heterogeneity in baseline epithelial nitric oxide synthase activity and/or the contribution of other noneosinophilic factors to epithelial nitric oxide synthase activity. FeNO is a promising biomarker, but at present some limits are highlighted. We would recommend that further research can be carried out by organizing studies aimed to obtain reliable reference values of FeNO and in order to better interpret FeNO measurements in clinical settings, taking also into account the influence of genetic and environmental factors.

Identifiers

PMID23902719
PMCPMC3750504
OpenAlexW2136779632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.